Gilead to buy Arresto for $225 million
This article was originally published in Scrip
Gilead Sciences is to acquire the privately-held US biotech Arresto Biosciences for $225 million to gain a pipeline of products targeting fibrotic diseases and cancer, including a candidate for the treatment of idiopathic pulmonary fibrosis (IPF). Gilead discontinued its Phase III trial of ambrisentan to treat IPF this week owing to lack of efficacy.
You may also be interested in...
With hepatitis C wrapped up, NASH is becoming the focus of liver disease R&D. Gilead, which has a number of NASH programs, has paid Phenex $100m for clinical progress with an in-licensed candidate for NASH and other liver diseases.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.